Cargando…

Design, production and immunomodulatory potency of a novel allergen bioparticle

Allergen immunotherapy (AIT) is the only disease-modifying treatment with evidence for sustained efficacy. However, it is poorly developed compared to symptomatic drugs. The main reasons come from treatment duration implying monthly injections during 3 to 5 years or daily sublingual use, and the ris...

Descripción completa

Detalles Bibliográficos
Autores principales: Gomord, Véronique, Stordeur, Virginie, Fitchette, Anne-Catherine, Fixman, Elizabeth D., Tropper, Guy, Garnier, Lorna, Desgagnes, Réjean, Viel, Sébastien, Couillard, Julie, Beauverger, Guillaume, Trepout, Sylvain, Ward, Brian J., van Ree, Ronald, Faye, Loic, Vézina, Louis-P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7707610/
https://www.ncbi.nlm.nih.gov/pubmed/33259521
http://dx.doi.org/10.1371/journal.pone.0242867
_version_ 1783617387504861184
author Gomord, Véronique
Stordeur, Virginie
Fitchette, Anne-Catherine
Fixman, Elizabeth D.
Tropper, Guy
Garnier, Lorna
Desgagnes, Réjean
Viel, Sébastien
Couillard, Julie
Beauverger, Guillaume
Trepout, Sylvain
Ward, Brian J.
van Ree, Ronald
Faye, Loic
Vézina, Louis-P
author_facet Gomord, Véronique
Stordeur, Virginie
Fitchette, Anne-Catherine
Fixman, Elizabeth D.
Tropper, Guy
Garnier, Lorna
Desgagnes, Réjean
Viel, Sébastien
Couillard, Julie
Beauverger, Guillaume
Trepout, Sylvain
Ward, Brian J.
van Ree, Ronald
Faye, Loic
Vézina, Louis-P
author_sort Gomord, Véronique
collection PubMed
description Allergen immunotherapy (AIT) is the only disease-modifying treatment with evidence for sustained efficacy. However, it is poorly developed compared to symptomatic drugs. The main reasons come from treatment duration implying monthly injections during 3 to 5 years or daily sublingual use, and the risk of allergic side-effects. To become a more attractive alternative to lifelong symptomatic drug use, improvements to AIT are needed. Among the most promising new immunotherapy strategies is the use of bioparticles for the presentation of target antigen to the immune system as they can elicit strong T cell and B cell immune responses. Virus-like particles (VLPs) are a specific class of bioparticles in which the structural and immunogenic constituents are from viral origin. However, VLPs are ill-suited for use in AIT as their antigenicity is linked to structure. Recently, synthetic biology has been used to produce artificial modular bioparticles, in which supramolecular assemblies are made of elements from heterogeneous biological sources promoting the design and use of in vivo-assembling enveloped bioparticles for viral and non-viral antigens presentation. We have used a coiled-coil hybrid assembly for the design of an enveloped bioparticle (eBP) that present trimers of the Der p 2 allergen at its surface, This bioparticle was produced as recombinant and in vivo assembled eBPs in plant. This allergen biotherapeutic was used to demonstrate i) the capacity of plants to produce synthetic supramolecular allergen bioparticles, and ii) the immunomodulatory potential of naturally-assembled allergen bioparticles. Our results show that allergens exposed on eBPs induced a very strong IgG response consisting predominantly of IgG2a in favor of the TH1 response. Finally, our results demonstrate that rDer p 2 present on the surface of BPs show a very limited potential to stimulate the basophil degranulation of patient allergic to this allergen which is predictive of a high safety potential.
format Online
Article
Text
id pubmed-7707610
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-77076102020-12-08 Design, production and immunomodulatory potency of a novel allergen bioparticle Gomord, Véronique Stordeur, Virginie Fitchette, Anne-Catherine Fixman, Elizabeth D. Tropper, Guy Garnier, Lorna Desgagnes, Réjean Viel, Sébastien Couillard, Julie Beauverger, Guillaume Trepout, Sylvain Ward, Brian J. van Ree, Ronald Faye, Loic Vézina, Louis-P PLoS One Research Article Allergen immunotherapy (AIT) is the only disease-modifying treatment with evidence for sustained efficacy. However, it is poorly developed compared to symptomatic drugs. The main reasons come from treatment duration implying monthly injections during 3 to 5 years or daily sublingual use, and the risk of allergic side-effects. To become a more attractive alternative to lifelong symptomatic drug use, improvements to AIT are needed. Among the most promising new immunotherapy strategies is the use of bioparticles for the presentation of target antigen to the immune system as they can elicit strong T cell and B cell immune responses. Virus-like particles (VLPs) are a specific class of bioparticles in which the structural and immunogenic constituents are from viral origin. However, VLPs are ill-suited for use in AIT as their antigenicity is linked to structure. Recently, synthetic biology has been used to produce artificial modular bioparticles, in which supramolecular assemblies are made of elements from heterogeneous biological sources promoting the design and use of in vivo-assembling enveloped bioparticles for viral and non-viral antigens presentation. We have used a coiled-coil hybrid assembly for the design of an enveloped bioparticle (eBP) that present trimers of the Der p 2 allergen at its surface, This bioparticle was produced as recombinant and in vivo assembled eBPs in plant. This allergen biotherapeutic was used to demonstrate i) the capacity of plants to produce synthetic supramolecular allergen bioparticles, and ii) the immunomodulatory potential of naturally-assembled allergen bioparticles. Our results show that allergens exposed on eBPs induced a very strong IgG response consisting predominantly of IgG2a in favor of the TH1 response. Finally, our results demonstrate that rDer p 2 present on the surface of BPs show a very limited potential to stimulate the basophil degranulation of patient allergic to this allergen which is predictive of a high safety potential. Public Library of Science 2020-12-01 /pmc/articles/PMC7707610/ /pubmed/33259521 http://dx.doi.org/10.1371/journal.pone.0242867 Text en © 2020 Gomord et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Gomord, Véronique
Stordeur, Virginie
Fitchette, Anne-Catherine
Fixman, Elizabeth D.
Tropper, Guy
Garnier, Lorna
Desgagnes, Réjean
Viel, Sébastien
Couillard, Julie
Beauverger, Guillaume
Trepout, Sylvain
Ward, Brian J.
van Ree, Ronald
Faye, Loic
Vézina, Louis-P
Design, production and immunomodulatory potency of a novel allergen bioparticle
title Design, production and immunomodulatory potency of a novel allergen bioparticle
title_full Design, production and immunomodulatory potency of a novel allergen bioparticle
title_fullStr Design, production and immunomodulatory potency of a novel allergen bioparticle
title_full_unstemmed Design, production and immunomodulatory potency of a novel allergen bioparticle
title_short Design, production and immunomodulatory potency of a novel allergen bioparticle
title_sort design, production and immunomodulatory potency of a novel allergen bioparticle
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7707610/
https://www.ncbi.nlm.nih.gov/pubmed/33259521
http://dx.doi.org/10.1371/journal.pone.0242867
work_keys_str_mv AT gomordveronique designproductionandimmunomodulatorypotencyofanovelallergenbioparticle
AT stordeurvirginie designproductionandimmunomodulatorypotencyofanovelallergenbioparticle
AT fitchetteannecatherine designproductionandimmunomodulatorypotencyofanovelallergenbioparticle
AT fixmanelizabethd designproductionandimmunomodulatorypotencyofanovelallergenbioparticle
AT tropperguy designproductionandimmunomodulatorypotencyofanovelallergenbioparticle
AT garnierlorna designproductionandimmunomodulatorypotencyofanovelallergenbioparticle
AT desgagnesrejean designproductionandimmunomodulatorypotencyofanovelallergenbioparticle
AT vielsebastien designproductionandimmunomodulatorypotencyofanovelallergenbioparticle
AT couillardjulie designproductionandimmunomodulatorypotencyofanovelallergenbioparticle
AT beauvergerguillaume designproductionandimmunomodulatorypotencyofanovelallergenbioparticle
AT trepoutsylvain designproductionandimmunomodulatorypotencyofanovelallergenbioparticle
AT wardbrianj designproductionandimmunomodulatorypotencyofanovelallergenbioparticle
AT vanreeronald designproductionandimmunomodulatorypotencyofanovelallergenbioparticle
AT fayeloic designproductionandimmunomodulatorypotencyofanovelallergenbioparticle
AT vezinalouisp designproductionandimmunomodulatorypotencyofanovelallergenbioparticle